These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 14607311)

  • 21. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
    Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
    Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.
    Potts LF; Park ES; Woo JM; Dyavar Shetty BL; Singh A; Braithwaite SP; Voronkov M; Papa SM; Mouradian MM
    Ann Neurol; 2015 Jun; 77(6):930-41. PubMed ID: 25820831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
    Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
    J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
    Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
    Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioid receptor gene expression in dopamine transporter knock-out mice in adult and during development.
    Le Moine C; Fauchey V; Jaber M
    Neuroscience; 2002; 112(1):131-9. PubMed ID: 12044478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
    Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
    Tomiyama M; Kimura T; Maeda T; Tanaka H; Kannari K; Baba M
    Synapse; 2004 Jun; 52(3):218-22. PubMed ID: 15065221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
    Vinuela A; Hallett PJ; Reske-Nielsen C; Patterson M; Sotnikova TD; Caron MG; Gainetdinov RR; Isacson O
    Brain; 2008 Dec; 131(Pt 12):3361-79. PubMed ID: 18988638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
    Glavan G
    Brain Res; 2008 Oct; 1236():216-24. PubMed ID: 18721798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
    Takuma K; Tanaka T; Takahashi T; Hiramatsu N; Ota Y; Ago Y; Matsuda T
    Eur J Pharmacol; 2012 May; 683(1-3):166-73. PubMed ID: 22449381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of striatal neuropeptide mRNAs: effects of the 5-HT(2) antagonist SR46349B in adult rats with a neonatal 6-hydroxydopamine lesion.
    Durand C; Mathieu-Kia AM; Besson MJ; Penit-Soria J
    J Neurosci Res; 2002 Jan; 67(1):86-92. PubMed ID: 11754083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
    Medhurst AD; Zeng BY; Charles KJ; Gray J; Reavill C; Hunter AJ; Shale JA; Jenner P
    Neuroscience; 2001; 105(2):353-64. PubMed ID: 11672603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.